MedTrace Logo

Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)

NCT03976518 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2024-03-01

No results posted yet for this study

Summary

This study is aimed to explore the antitumor activity and the safety profile of atezolizumab in pretreated advanced NSCLC patients with rare histological subtypes.

Conditions

Interventions

DRUG

Atezolizumab

Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).

Sponsors & Collaborators

  • AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology

    collaborator UNKNOWN

  • Istituto Toscano Tumori

    collaborator OTHER

  • YGHEA, CRO Division of Ecol Studio spa

    collaborator INDUSTRY

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • AOU S. Orsola Malpighi - Clinical Trial Office

    collaborator UNKNOWN

  • Silvano Chiapparoli Logistica SpA

    collaborator UNKNOWN

  • Roche SpA

    collaborator UNKNOWN

  • Gruppo Oncologico Italiano di Ricerca Clinica

    lead OTHER

Principal Investigators

  • Andrea Ardizzoni, MD · Dept Oncology-Haematology - S.Orsola-Malpighi Hospital - Bologna - Italy

  • Francesco Gelsomino, MD · Dept Oncology-Haematology - S.Orsola-Malpighi Hospital - Bologna - Italy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-07
Primary Completion
2024-02-12
Completion
2024-02-12

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03976518 on ClinicalTrials.gov